Q1 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Q1 mid single-digit sales and high single-digit Core Oplnc growth
Change vs. PY
Group1
USD million
Net sales
Core operating income
Operating income
Net income
Q1 2022
% USD
%CC
12,531
1
4,083
3
2,852
18
2,219
8
15
Growth ex. prior year Roche income
23
32
Core EPS (USD)
1.46
-4
Growth ex. prior year Roche income
6
EPS (USD)
1.00
10
17
Growth ex. prior year Roche income
25
56652
2272
9
12
34
Free cash flow
920
-42
Growth ex. prior year Roche dividend
-14
1. Constant currencies (cc), core results and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found on page 35 of the Condensed Interim Financial Report. A reconciliation of 2021 IFRS results and non-
IFRS measures core results and free cash flow to exclude the impacts of the 2021 divestment of our Roche investment can be found on page 40 of the Condensed Interim Financial Report. The free cash flow impact represents the dividend
received in Q1 2021 from Roche in relation to the distribution of its 2020 net income.
22 Investor Relations | Q1 2022 Results
ā NOVARTIS | Reimagining MedicineView entire presentation